You’re not going to tell me you read the last three days’ columns in their entirety – they were much too long, and much of that time the web site was down anyway. So go read ’em now. Especially the item about comparative oinkiness.
Today, let me just note that one of the firms that has been recommending Nitromed stock, Friedman, Billings, Ramsey & Co., yesterday reduced its forecasts for sales of BiDil, the company’s (only) product, from $17 million in 2005 to $7 million – 58% lower than previously. From $134 million in 2006 to $59.5 million – 55% lower. And from $232 million in 2007 to $134 million – 42% lower. And since sales are not all profit (the pills themselves cost almost nothing to produce, but there is a projected $120 million or so a year in other expenses), the reduction in expected profit in those years is presumably even steeper.
So by how much has this firm reduced its ‘target price’ for the stock, given that they think sales will be only half what they thought before? By 10%, from $32 to $29. (They now think 2008 will be the year big profits start to flow.)
NTMD closed at $16.32 last night, down from just over $22 when we first started talking about it July 6. Anything is possible, of course. But presuming you went into this with money you could truly afford to lose (as you still could): don’t sell your puts. Oink, oink.
Quote of the Day
Farming looks mighty easy when your plow is a pencil and you're a thousand miles from the corn field.~Dwight Eisnehower
Request email delivery
- Feb 21:
The Case For A Conservative Boycott
- Feb 19:
You Don’t Think Smart People Can Be Scammed?
- Feb 17:
Long-Weekend Reading: The Compelling Nonpartisan Case For A Boycott
- Feb 15:
Coats: We Are Under Attack
- Feb 14:
The Rabbi’s Hat
- Feb 13:
TED’s Playlist for a Long Life
- Feb 12:
Pre-Empting The October Surprise
- Feb 9:
The Least Worst — and Six Trends For 2018
- Feb 8:
My Friend Wrote A Book; WheelTug Signed SunExpress
- Feb 6:
The Market. But First, Humor.
- Feb 21: